慢性骨髓性白血病是一种骨髓增殖性疾病,主要以染色体易位、致使产生了编码有融合基因BCR-ABL的费城染色体为特征。由于BCR-ABL基因的产物是一种已失去控制的激酶,故会刺激细胞增殖并介导对细胞程序性死亡(凋亡)的耐受性。作为全球范围内获准上市的第一个酪氨酸激酶抑制 Chronic myelogenous leukemia is a myeloproliferative disorder characterized primarily by chromosomal translocations that result in the generation of Philadelphia chromosomes encoding the fusion gene BCR-ABL. Because the product of the BCR-ABL gene is an uncontrolled kinase, it stimulates cell proliferation and mediates resistance to programmed cell death (apoptosis). As the first worldwide tyrosine kinase inhibitor approved